Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, CorMedix Inc (NASDAQ: CRMD) closed at $11.12 down -1.07% from its previous closing price of $11.24. In other words, the price has decreased by -$1.07 from its previous closing price. On the day, 1.83 million shares were traded. CRMD stock price reached its highest trading level at $11.34 during the session, while it also had its lowest trading level at $10.95.
Ratios:
For a deeper understanding of CorMedix Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.54. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 7.82. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On March 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $18.Leerink Partners initiated its Outperform rating on March 07, 2025, with a $18 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 12 ’25 when DUNTON ALAN W sold 10,000 shares for $13.13 per share. The transaction valued at 131,300 led to the insider holds 40,250 shares of the business.
Todisco Joseph sold 50,000 shares of CRMD for $650,000 on Sep 12 ’25. The Chief Executive Officer now owns 509,496 shares after completing the transaction at $13.00 per share. On Sep 12 ’25, another insider, DUNTON ALAN W, who serves as the Director of the company, bought 10,000 shares for $13.10 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 830096768 and an Enterprise Value of 639820288. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.89, and their Forward P/E ratio for the next fiscal year is 4.58. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.15 while its Price-to-Book (P/B) ratio in mrq is 3.76. Its current Enterprise Value per Revenue stands at 5.267 whereas that against EBITDA is 12.834.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.87, which has changed by 0.3813665 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is -9.32%, while the 200-Day Moving Average is calculated to be 1.49%.
Shares Statistics:
For the past three months, CRMD has traded an average of 3.38M shares per day and 2997380 over the past ten days. A total of 74.62M shares are outstanding, with a floating share count of 69.67M. Insiders hold about 10.75% of the company’s shares, while institutions hold 44.08% stake in the company. Shares short for CRMD as of 1756425600 were 11886496 with a Short Ratio of 4.93, compared to 1753920000 on 10679715. Therefore, it implies a Short% of Shares Outstanding of 11886496 and a Short% of Float of 16.09.
Earnings Estimates
The market rating of CorMedix Inc (CRMD) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.73, with high estimates of $1.02 and low estimates of $0.38.
Analysts are recommending an EPS of between $2.07 and $1.31 for the fiscal current year, implying an average EPS of $1.78. EPS for the following year is $2.43, with 7.0 analysts recommending between $3.24 and $1.72.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $65.63M this quarter.It ranges from a high estimate of $72.9M to a low estimate of $62M. As of the current estimate, CorMedix Inc’s year-ago sales were $11.46MFor the next quarter, 7 analysts are estimating revenue of $102.94M. There is a high estimate of $117.8M for the next quarter, whereas the lowest estimate is $65M.
A total of 7 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $263.7M, while the lowest revenue estimate was $205.82M, resulting in an average revenue estimate of $247.41M. In the same quarter a year ago, actual revenue was $43.47MBased on 7 analysts’ estimates, the company’s revenue will be $395.39M in the next fiscal year. The high estimate is $487.26M and the low estimate is $303.19M.
